Literature DB >> 15737622

A boundary for histone acetylation allows distinct expression patterns of the Ad4BP/SF-1 and GCNF loci in adrenal cortex cells.

Satoru L Ishihara1, Ken-ichirou Morohashi.   

Abstract

Ad4BP/SF-1 is a nuclear receptor whose expression is restricted to tissues involved in steroid hormone synthesis such as the adrenal cortex and gonads. Recent sequence data analysis has shown that the Ad4BP/SF-1 gene is located only 13kb downstream of the last exon of the neighboring GCNF gene that is expressed in some neurons and gonadal germ cells. Despite the close proximity of the two genes, regulatory elements from one do not interfere with the transcription of the neighboring gene, resulting in distinct expression patterns of Ad4BP/SF-1 and GCNF. This observation has led to the prediction that an insulator element must exist between the two loci to establish independent transcription units. We performed DNase I hypersensitivity assays on the adrenal cortex cell line, Y-1, to test for the existence of an insulator. Three hypersensitive sites were identified in the region spanning 2.1kb between the last exon of GCNF and the first exon of Ad4BP/SF-1. The most upstream site contains a binding site for CTCF, a known insulator protein, while the other sites are predicted to associate with the nuclear matrix. Chromatin immunoprecipitation analysis using anti-acetylated histone H3 and H4 antibodies showed a discontinuous pattern of histone H3 and H4 acetylation upstream of these sites. Our data suggest that the chromatin architecture specialized by CTCF and the nuclear matrix contribute to the distinct pattern of transcriptional regulation of these genes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15737622     DOI: 10.1016/j.bbrc.2005.02.011

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Decondensing the protamine domain for transcription.

Authors:  Rui Pires Martins; Stephen A Krawetz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-01       Impact factor: 11.205

2.  Dicer deficiency reveals microRNAs predicted to control gene expression in the developing adrenal cortex.

Authors:  Kenneth T Krill; Katherine Gurdziel; Joanne H Heaton; Derek P Simon; Gary D Hammer
Journal:  Mol Endocrinol       Date:  2013-03-21

Review 3.  Steroidogenic factor-1 is a sphingolipid binding protein.

Authors:  Aarti N Urs; Eric Dammer; Samuel Kelly; Elaine Wang; Alfred H Merrill; Marion B Sewer
Journal:  Mol Cell Endocrinol       Date:  2006-12-29       Impact factor: 4.102

Review 4.  Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease.

Authors:  Bernard P Schimmer; Perrin C White
Journal:  Mol Endocrinol       Date:  2010-03-04

5.  Multiple Signaling Pathways Coordinate CYP17 Gene Expression in the Human Adrenal Cortex.

Authors:  Marion B Sewer; Donghui Li; Eric B Dammer; Srinath Jagarlapudi; Natasha Lucki
Journal:  Acta Chim Slov       Date:  2008-01-01       Impact factor: 1.735

6.  Cyclic AMP-stimulated interaction between steroidogenic factor 1 and diacylglycerol kinase theta facilitates induction of CYP17.

Authors:  Donghui Li; Aarti N Urs; Jeremy Allegood; Adam Leon; Alfred H Merrill; Marion B Sewer
Journal:  Mol Cell Biol       Date:  2007-07-30       Impact factor: 4.272

7.  Acid ceramidase (ASAH1) represses steroidogenic factor 1-dependent gene transcription in H295R human adrenocortical cells by binding to the receptor.

Authors:  Natasha C Lucki; Donghui Li; Sibali Bandyopadhyay; Elaine Wang; Alfred H Merrill; Marion B Sewer
Journal:  Mol Cell Biol       Date:  2012-08-27       Impact factor: 4.272

Review 8.  Multiple roles for sphingolipids in steroid hormone biosynthesis.

Authors:  Natasha C Lucki; Marion B Sewer
Journal:  Subcell Biochem       Date:  2008

Review 9.  Complex assembly on the human CYP17 promoter.

Authors:  Marion B Sewer; Srinath Jagarlapudi
Journal:  Mol Cell Endocrinol       Date:  2008-10-19       Impact factor: 4.102

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.